Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody three years later as the ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...